OBJECTIVE: The impact of prolonged subclinical hyperthyroidism on quality of life is unclear. Therefore, we evaluated quality of life in patients with differentiated thyroid carcinoma (DTC) on TSH-suppressivethyroxine therapy as a model for subclinical hyperthyroidism and we investigated whether restoration to euthyroidism affects quality of life. DESIGN: We performed a prospective, single-blinded, placebo-controlled, randomized trial of 6 months' duration with two parallel groups. PATIENTS AND METHODS: Twenty-four subjects with a history of differentiated thyroid carcinoma with >; 10 years TSH-suppressive therapy with L-thyroxine completed the study. L-thyroxine dose was replaced by study medication containing L-thyroxine or L-thyroxine plus placebo. Medication was titrated to establish continuation of TSH suppression (low-TSH group) and euthyroidism (euthyroid group). Both groups consisted of 12 patients. We evaluated quality of life using five validated questionnaires. RESULTS: At baseline, the somatic disorder questionnaire (SDQ) indicated more somatic dysfunction in patients as compared with reference values, whereas the depression score (HADS) revealed a better score than the reference group. All other quality of life parameters were normal. At baseline, no significant differences between the low-TSH and the euthyroidism groups were observed. After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values. In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003), although this parameter did not differ from the reference group at baseline. A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed. No improvement in the SDQ score was observed. CONCLUSION: In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved. Restoration of euthyroidism in general does not affect quality of life.
RCT Entities:
OBJECTIVE: The impact of prolonged subclinical hyperthyroidism on quality of life is unclear. Therefore, we evaluated quality of life in patients with differentiated thyroid carcinoma (DTC) on TSH-suppressive thyroxine therapy as a model for subclinical hyperthyroidism and we investigated whether restoration to euthyroidism affects quality of life. DESIGN: We performed a prospective, single-blinded, placebo-controlled, randomized trial of 6 months' duration with two parallel groups. PATIENTS AND METHODS: Twenty-four subjects with a history of differentiated thyroid carcinoma with > 10 years TSH-suppressive therapy with L-thyroxine completed the study. L-thyroxine dose was replaced by study medication containing L-thyroxine or L-thyroxine plus placebo. Medication was titrated to establish continuation of TSH suppression (low-TSH group) and euthyroidism (euthyroid group). Both groups consisted of 12 patients. We evaluated quality of life using five validated questionnaires. RESULTS: At baseline, the somatic disorder questionnaire (SDQ) indicated more somatic dysfunction in patients as compared with reference values, whereas the depression score (HADS) revealed a better score than the reference group. All other quality of life parameters were normal. At baseline, no significant differences between the low-TSH and the euthyroidism groups were observed. After 6 months, none of the quality of life parameters in the low-TSH group was different from baseline values. In the euthyroid group, motivation was significantly improved (Multidimensional Fatigue Index-20, P = 0.003), although this parameter did not differ from the reference group at baseline. A probable worsening in role limitations as a result of physical problems (Short Form-36; P = 0.050) was observed. No improvement in the SDQ score was observed. CONCLUSION: In summary, quality of life in patients with DTC and long-term subclinical hyperthyroidism in general is preserved. Restoration of euthyroidism in general does not affect quality of life.
Authors: Mary H Samuels; Irina Kolobova; Anne Smeraglio; Dawn Peters; Jeri S Janowsky; Kathryn G Schuff Journal: J Clin Endocrinol Metab Date: 2014-01-13 Impact factor: 5.958
Authors: P Miccoli; M N Minuto; R Paggini; P Rucci; A Oppo; G Donatini; F Golia; L Novelli; M Carlini; L Dell'Osso Journal: J Endocrinol Invest Date: 2007-11 Impact factor: 4.256
Authors: Branka R Bukvic; Vladan R Zivaljevic; Sandra B Sipetic; Aleksandar D Diklic; Katarina M Tausanovic; Ivan R Paunovic Journal: Langenbecks Arch Surg Date: 2014-07-08 Impact factor: 3.445
Authors: David T Hughes; David Reyes-Gastelum; Kevin J Kovatch; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: Surgery Date: 2019-09-30 Impact factor: 3.982
Authors: Olga Husson; Willy-Anne Nieuwlaat; Wilma A Oranje; Harm R Haak; Lonneke V van de Poll-Franse; Floortje Mols Journal: Thyroid Date: 2013-07-25 Impact factor: 6.568
Authors: Ji In Lee; Soo Hyun Kim; Alice H Tan; Hee Kyung Kim; Hye Won Jang; Kyu Yeon Hur; Jae Hyeon Kim; Kwang-Won Kim; Jae Hoon Chung; Sun Wook Kim Journal: Health Qual Life Outcomes Date: 2010-09-15 Impact factor: 3.186
Authors: David Taïeb; Karine Baumstarck-Barrau; Frédéric Sebag; Cécile Fortanier; Catherine De Micco; Anderson Loundou; Pascal Auquier; Fausto F Palazzo; Jean-françois Henry; Olivier Mundler Journal: Health Qual Life Outcomes Date: 2011-05-13 Impact factor: 3.186